Sapanisertib and Osimertinib in Treating Patients With Stage IV EGFR Mutation Positive Non-small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor
about
Sapanisertib and Osimertinib in Treating Patients With Stage IV EGFR Mutation Positive Non-small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor
description
clinical trial
@en
klinisch onderzoek
@nl
name
Sapanisertib and Osimertinib i ...... EGFR Tyrosine Kinase Inhibitor
@en
type
label
Sapanisertib and Osimertinib i ...... EGFR Tyrosine Kinase Inhibitor
@en
prefLabel
Sapanisertib and Osimertinib i ...... EGFR Tyrosine Kinase Inhibitor
@en
P6153
P1476
A Phase 1 Trial of MLN0128 (TA ...... EGFR Tyrosine Kinase Inhibitor
@en
P3098
NCT02503722
P4844
P580
2016-10-13T00:00:00Z
P582
2019-08-31T00:00:00Z